V
The startup develops antiviral therapeutics that inhibit viral replication by targeting essential protein-protein interactions, effectively disrupting the lifecycle of various human pathogenic viruses. This technology addresses the critical need for effective treatments against respiratory and viral diseases that significantly impact vulnerable populations.
Cognin-les-Gorges, France
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops antiviral therapeutics that inhibit viral replication by targeting essential protein-protein interactions, effectively disrupting the lifecycle of various human pathogenic viruses. This technology addresses the critical need for effective treatments against respiratory and viral diseases that significantly impact vulnerable populations.